Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Evangelia S. Makri"'
Autor:
Despoina Ioannidou, Evangelia S. Makri, Stergios A. Polyzos, Charikleia Ntenti, Dimitrios Agapakis, Georgios Germanidis, Antonis Goulas
Publikováno v:
Exploration of Medicine, Vol 4, Iss 1, Pp 16-22 (2023)
Aim: One single nucleotide polymorphism (SNP) rs738409 in the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene has been considered a major genetic risk factor of nonalcoholic fatty liver disease (NAFLD). Data have indicated that N
Externí odkaz:
https://doaj.org/article/ab2b0c45edd04ae7a21515a7c07db4a8
Autor:
Evangelia S. Makri, Konstantinos Xanthopoulos, Panagiotis Parasidis, Eleftheria Makri, Anastasia Tsingotjidou, Angeliki Cheva, Iris Ballaouri, Spyridon Gerou, Antonis Goulas, Stergios A. Polyzos
Publikováno v:
Journal of Atherosclerosis Prevention and Treatment. 13:91-95
Aim: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease affecting a large proportion of the general population (25%). The aim of this study was to evaluate the effect of a sodium-glucose co-transporter 2 inhibitor, empagliflozin, on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::504ebf149343d9c4546c48dfcbc93777
https://doi.org/10.53590/japt.02.1037
https://doi.org/10.53590/japt.02.1037
Publikováno v:
Journal of Atherosclerosis Prevention and Treatment. 13:17-25
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease affecting millions of people worldwide with potentially serious complications that may lead to mortality and constitute a significant socioeconomic burden. Although modern lifestyle,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4423a8d98524d8f3fb6a87790fe5e9e
https://doi.org/10.53590/japt.02.1030
https://doi.org/10.53590/japt.02.1030
Autor:
Christina Tontikidou, Evangelia S Makri, Kleo Evripidou, Dimitrios G Goulis, Antonis Goulas, Stergios A Polyzos
Publikováno v:
Journal of gastroenterology and hepatologyReferences. 37(10)
There are conflicting data on adiponectin concentrations in nonalcoholic fatty liver disease (NAFLD). The main aim was to compare circulating total adiponectin concentrations in NAFLD patients with versus without liver fibrosis.A systematic search wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2312575b8ce0b9afcb4a352a7e2ddb34
https://pubmed.ncbi.nlm.nih.gov/35748302
https://pubmed.ncbi.nlm.nih.gov/35748302
Publikováno v:
Journal of Personalized Medicine. 12:1166
Nonalcoholic fatty liver disease (NAFLD) is considered a highly prevalent disease associated with various co-morbidities that lead to socioeconomic burden. Despite large-scale investigation, no pharmacological treatment has been approved specifically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f16f4c7e95f653cdffa5b3b3ead03cd7
https://doi.org/10.3390/jpm12071166
https://doi.org/10.3390/jpm12071166
Autor:
Makri ES; First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki (Evangelia S. Makri, Eleftheria Makri, Antonis Goulas, Stergios A. Polyzos)., Makri E; First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki (Evangelia S. Makri, Eleftheria Makri, Antonis Goulas, Stergios A. Polyzos)., Goulas A; First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki (Evangelia S. Makri, Eleftheria Makri, Antonis Goulas, Stergios A. Polyzos)., Xanthopoulos K; Laboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki (Konstantinos Xanthopoulos).; Institute of Applied Biosciences, Centre for Research and Technology, Thessaloniki (Konstantinos Xanthopoulos), Greece., Polyzos SA; First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki (Evangelia S. Makri, Eleftheria Makri, Antonis Goulas, Stergios A. Polyzos).
Publikováno v:
Annals of gastroenterology [Ann Gastroenterol] 2024 May-Jun; Vol. 37 (3), pp. 280-290. Date of Electronic Publication: 2024 Apr 30.